Published in Clin Lung Cancer on August 10, 2011
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med (2013) 1.36
Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release (2013) 1.12
Andrographolide inhibits proliferation of human lung cancer cells and the related mechanisms. Int J Clin Exp Med (2014) 0.85
Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One (2012) 0.85
TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer. PLoS One (2014) 0.84
Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine (2014) 0.81
The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget (2016) 0.80
Adjuvant chemotherapy after resection of N1 non-small cell lung cancer: differential impact of new evidence on physician and patient decisions. J Thorac Dis (2015) 0.80
Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. Oncologist (2015) 0.76
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet (2004) 2.05
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol (2010) 1.83
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res (2014) 1.59
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol (2012) 1.48
Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer (2011) 1.41
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer (2010) 1.34
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res (2004) 1.32
Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget (2011) 1.24
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One (2013) 1.05
Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer (2003) 1.00
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol (2015) 0.99
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol (2011) 0.96
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol (2012) 0.95
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol (2013) 0.92
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov (2013) 0.91
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol (2014) 0.89
Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer (2013) 0.88
Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer (2011) 0.85
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther (2011) 0.84
Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol (2004) 0.84
Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe. Eur Respir J (2013) 0.81
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol (2006) 0.80
How could pharmacogenomics help improve patient survival? Lung Cancer (2007) 0.80
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2005) 0.79
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol (2014) 0.79
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer (2013) 0.78
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer (2008) 0.78
Pemetrexed in previously treated non-small-cell lung cancer. Oncology (Williston Park) (2004) 0.78
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol (2014) 0.77
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer (2009) 0.77
Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). Clin Transl Oncol (2010) 0.77
Ganitumab for the treatment of small-cell lung cancer. Expert Opin Investig Drugs (2014) 0.76
Targeted therapies development in the treatment of advanced nonsmall cell lung cancer. J Biomed Biotechnol (2011) 0.76
PI3K Pathway in NSCLC. Front Oncol (2012) 0.75
Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. J Thorac Dis (2013) 0.75
Women in oncology: progress, challenges, and keys to success. Am Soc Clin Oncol Educ Book (2013) 0.75
ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep (2015) 0.75
Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer (2011) 0.75
Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Future Oncol (2005) 0.75